<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">
  <url>
    <loc>https://dermsquared.com/case-studies/che-despite-systemic-ad-control</loc>
    <lastmod>2025-12-30T18:59:51.141Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://dermsquared.com/case-studies/after-dupilumab-failure</loc>
    <lastmod>2025-11-11T14:46:59.956Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://dermsquared.com/case-studies/changing-landscape-topical-fc25-preview</loc>
    <lastmod>2025-10-17T14:40:12.125Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://dermsquared.com/case-studies/jacked-on-jaks-ad</loc>
    <lastmod>2026-03-17T18:22:28.152Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://dermsquared.com/case-studies/spesolimab-erythrodermic-gpp</loc>
    <lastmod>2026-03-17T18:25:14.378Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://dermsquared.com/case-studies/tapinarof-recalcitrant-ad-pediatric</loc>
    <lastmod>2026-03-17T18:25:32.824Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://dermsquared.com/case-studies/subcutaneous-spesolimab-patient-chronic-recurrent-gpp</loc>
    <lastmod>2026-03-17T18:25:20.551Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://dermsquared.com/case-studies/remarkable-severe-recalcitrant-psoriasis</loc>
    <lastmod>2026-03-17T18:25:06.962Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://dermsquared.com/case-studies/management-basal-cell-carcinoma</loc>
    <lastmod>2026-03-17T18:24:27.760Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://dermsquared.com/case-studies/tapinarof-plaques-boney-prominences</loc>
    <lastmod>2026-03-17T18:25:26.872Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://dermsquared.com/case-studies/rash-decisions-rapid-sustained-clearance-severe-psoriasis-il-17-inhibition</loc>
    <lastmod>2026-03-17T18:24:52.294Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://dermsquared.com/case-studies/rash-decisions-nonsegmental-vitiligo-topical-jak-inhibitor-phototherapy</loc>
    <lastmod>2026-03-17T18:24:40.040Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://dermsquared.com/case-studies/rash-decisions-rapid-clearance-recalcitrant-psoriasis-il-17-inhibitor</loc>
    <lastmod>2026-03-17T18:24:46.290Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://dermsquared.com/case-studies/rash-decisions-successful-ruxolitinib-nonsegmental-periorbital-vitiligo</loc>
    <lastmod>2026-03-17T18:24:59.408Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://dermsquared.com/case-studies/rash-decisions-assessing-prognosis-squamous-cell-carcinoma</loc>
    <lastmod>2026-03-17T18:22:34.743Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://dermsquared.com/case-studies/rash-decisions-life-saving-treatment-rapid-eruption-pustules</loc>
    <lastmod>2023-05-10T20:19:05.786Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://dermsquared.com/case-studies/rash-decisions-non-steroidal-topical-therapy-atopic-dermatitis</loc>
    <lastmod>2026-03-17T18:24:33.900Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
</urlset>